Selexis & Teneobio have signed CLAs for the development of Teneobio’s UniAbs™, a new class of multi-specific biologics, for the treatment of multiple myeloma, lymphoma and prostate cancer
The development will be based on PeptiDream’s proprietary drug discovery platform, PDPS (Peptide Discovery Platform System), and JSR’s extensive knowledge of affinity separation technology.
Selexis SA and KBI Biopharma, Inc. have announced a new collaboration with ZyVersa Therapeutics to advance development of ZyVersa’s lead inflammasome inhibitor, IC 100, for the treatment of multi...
The new facility provides state-of-the-art laboratory and work space for JSR’s Separations Sciences Group (SSG) to focus on applications development, customer support and training.
Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumour indications as the basis of bispecific and combination therapies
Research Cell Banks Produce Therapeutic Proteins in Just Eight Weeks as Validated in Oral Presentation on Integration of Berkeley Lights’ Beacon Optofluidic Platform with Selexis’ Workflow and Clon...
Selexis SA and Generium JSC today announced that a fifth Selexis SUREtechnology Platform™-generated biological product has been approved for marketing.
Partnership combines breakthrough organoid technology with the world’s largest PDX collection to create a unique patient-derived translational research platform
